Share Prices & Company Research

Market News

26 Feb 2021 | 09:06

Silence to get $2m milestone payment from Mallinckrodt

(Sharecast News) - Silence Therapeutics announced on Friday that it would receive a $2m (£1.43m) milestone payment following the start of work on a third target being explored under its ongoing RNAi research collaboration with Mallinckrodt, for the treatment of complement pathway-mediated diseases. The AIM-traded firm said the collaboration was focused on the development and commercialisation of RNAi therapeutics designed to inhibit, or "silence", the complement cascade, which is a group of proteins that are involved in the immune system and play a role in the development of inflammation.

Using Silence's proprietary mRNAi 'GOLD', or GalNAc Oligonucleotide Discovery, platform, each target in the collaboration would be investigated before progressing into clinical development.

"Our expanding collaboration with Mallinckrodt highlights our commitment to maximise our mRNAi GOLD platform through partnerships while also advancing our pipeline of wholly-owned programs," said president and chief executive officer Mark Rothera.

"We believe the potential for our platform to target disease-associated genes in the liver is substantial and continue to see real promise in our siRNA therapies to treat complement-mediated disorders."

At 0839 GMT, shares in Silence Therapeutics were up 0.26% at 589.5p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 14th May 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.